Fig. 4
From: DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms
DCYTB predicts treatment outcome in tamoxifen and chemotherapy-treated cohorts. a Kaplan-Meier analysis of ER+ patients in cohort #1 who received tamoxifen monotherapy subsetted by high and low DCYTB expression, p = 5.7e-05, n = 263, log-rank test. b Kaplan-Meier analysis of patients who were ERBB2- (Her2-) and either ER+ or ER- and had been treated with taxane-anthracycline neoadjuvant chemotherapy (and tamoxifen if ER+) followed by surgery (GSE25055) [40], p = 0.003, n = 303, log-rank test. DCYTB duodenal cytochrome b